|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1993-3-1
|
|
pubmed:abstractText |
Chemotherapy may induce overall (complete plus partial) response rates of more than 50% and complete response rates up to 25% in extensive small-cell lung cancer (stage IIIB or IV), but survival is generally limited to 8-12 months. Interleukin-2 (IL-2) has demonstrated activity against this disease in vitro and has produced regression in melanoma and renal cell carcinoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
17
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
316-20
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:8381188-Adult,
pubmed-meshheading:8381188-Aged,
pubmed-meshheading:8381188-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8381188-Carcinoma, Small Cell,
pubmed-meshheading:8381188-Cisplatin,
pubmed-meshheading:8381188-Cyclophosphamide,
pubmed-meshheading:8381188-Doxorubicin,
pubmed-meshheading:8381188-Etoposide,
pubmed-meshheading:8381188-Female,
pubmed-meshheading:8381188-Humans,
pubmed-meshheading:8381188-Interleukin-2,
pubmed-meshheading:8381188-Lung Neoplasms,
pubmed-meshheading:8381188-Male,
pubmed-meshheading:8381188-Middle Aged,
pubmed-meshheading:8381188-Prospective Studies
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.
|
|
pubmed:affiliation |
Department of Internal Medicine, University of Iowa College of Medicine, Iowa City.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
